Field effectiveness of vaccination against tick-borne encephalitis (Q43040713)

12 November 2017

Field effectiveness of vaccination against tick-borne encephalitis (English)

1 reference

12 November 2017

4

Michael Kundi

1 reference

12 November 2017

Franz X Heinz

1

1 reference

12 November 2017

Heidemarie Holzmann

series ordinal

2

1 reference

12 November 2017

Astrid Essl

series ordinal

3

1 reference

12 November 2017

language of work or name

English

0 references

publication date

31 August 2007

1 reference

12 November 2017

1 reference

12 November 2017

25

1 reference

12 November 2017

43

1 reference

12 November 2017

7559-7567

1 reference

12 November 2017

Tick‐Borne Encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Epidemiology and ecology of TBE relevant to the production of effective vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Molecular epidemiology of tick-borne encephalitis virus: cross-protection between European and Far Eastern subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

7 January 2021

Tick-borne flaviviruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Characterization of tick-borne encephalitis virus from Estonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Siberian subtype tickborne encephalitis virus, Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Tick-borne encephalitis virus in Lithuania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Tick-borne encephalitis with hemorrhagic syndrome, Novosibirsk region, Russia, 1999.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Main features of tick-borne encephalitis eco-epidemiology in Russia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Tick-borne encephalitis--pathogenesis, clinical course and long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

7 January 2021

History of TBE vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Preparation of a highly purified vaccine against tick-borne encephalitis by continuous flow zonal ultracentrifugation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

TBE vaccination and the Austrian experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Immunogenicity and reactogenicity of a highly purified vaccine against tick‐borne encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

A randomized phase II study of a new tick-borne encephalitis vaccine using three different doses and two immunization regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Protection against tick-borne encephalitis with a new vaccine formulation free of protein-derived stabilizers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Impact of hepatitis B vaccination on hepatitis B disease and nucleic acid testing in high-prevalence populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Protection against Japanese encephalitis by inactivated vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Diagnosis of tick-borne encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Fragile transmission cycles of tick-borne encephalitis virus may be disrupted by predicted climate change

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Immunosenescence of ageing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Insufficient protection for healthy elderly adults by tetanus and TBE vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Immunity and ageing in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994-98: a prospective study of 656 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Tick-borne encephalitis (TBE) in Germany and clinical course of the disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Severe forms of tick-borne meningoencephalitis in Slovenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Persistence of protective immunity following vaccination against tick-borne encephalitis--longer than expected?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

Persistence of antibodies after vaccination against tick-borne encephalitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.024

10.1016/J.VACCINE.2007.08.024

7 January 2021

Identifiers

DOI

1 reference

12 November 2017

1 reference